UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 222

Sortiert nach

Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells

Mucosal immunology, 2014-03, Vol.7 (2), p.428-439

2014

Volltextzugriff (PDF)

Elevated IL-33 expression is associated with pediatric eosinophilic esophagitis, and exogenous IL-33 promotes eosinophilic esophagitis development in mice

American journal of physiology: Gastrointestinal and liver physiology, 2016-01, Vol.310 (1), p.G13-G25

2016

Volltextzugriff (PDF)

278. Immunological outcome in patients after resection of colorectal cancer

European journal of surgical oncology, 2014-11, Vol.40 (11), p.S111-S111

2014

Volltextzugriff (PDF)

PMO-088A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression

Gut, 2012-07, Vol.61 (Suppl 2), p.A109-A109

2012

Volltextzugriff (PDF)

How to Treat the Ewing's Family of Sarcomas in Adult Patients

The oncologist (Dayton, Ohio), 2006-01, Vol.11 (1), p.65-72

2006

Volltextzugriff (PDF)

PWE-151Cell-MediatedImmune Recognition of Cea Is Associated with Early Tumour Recurrence Following Resection of Colorectal Cancer

Gut, 2013-06, Vol.62 (Suppl 1), p.A192-A193

2013

Volltextzugriff (PDF)

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

Cancer chemotherapy and pharmacology, 2005-04, Vol.55 (4), p.379-386

2005

Volltextzugriff (PDF)

9421 The role of chemotherapy in aggressive fibromatosis

European journal of cancer supplements, 2009, Vol.7 (2), p.596-596

2009

Volltextzugriff (PDF)

9404 A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS])

European journal of cancer supplements, 2009, Vol.7 (2), p.591-591

2009

Volltextzugriff (PDF)

PWE-152SelectiveLoss of Oncofoetal Antigen 5T4-Specific T Cell Response Correlates with Progression of Colorectal Cancer

Gut, 2013-06, Vol.62 (Suppl 1), p.A193-A193

2013

Volltextzugriff (PDF)

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

European journal of cancer supplements, 2008, Vol.6 (12), p.19-19

2008

Volltextzugriff (PDF)

126 INVITED New drug treatment for cancer in 2007 – real progress at last?

European journal of cancer supplements, 2007, Vol.5 (4), p.35-35

2007

Volltextzugriff (PDF)

Neoadjuvant and Adjuvant Therapy for Extremity Soft Tissue Sarcomas

Hematology/oncology clinics of North America, 2005-06, Vol.19 (3), p.489-500

2005

Volltextzugriff (PDF)

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

The lancet oncology, 2010-02, Vol.11 (2), p.129-135

2010

Volltextzugriff (PDF)

388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma

European journal of cancer supplements, 2008, Vol.6 (12), p.122-122

2008

Volltextzugriff (PDF)

7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas

European journal of cancer supplements, 2007, Vol.5 (4), p.403-404

2007

Volltextzugriff (PDF)

Chemotherapy in advanced pleomorphic sarcomas: The experience of the Royal Marsden Hospital (RMH)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e20510-e20510

2011

Volltextzugriff (PDF)

Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.10523-10523

2009

Volltextzugriff (PDF)

Creatinine clearance and serum albumin as factors for encephalopathy with ambulatory 14-day infusional ifosfamide for advanced liposarcomas

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.10087-10087

2011

Volltextzugriff (PDF)

The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e20507-e20507

2011

Volltextzugriff (PDF)

Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined analysis from two European referral institutions

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.10023-10023

2011

Volltextzugriff (PDF)

Treatment of aggressive fibromatosis with pegylated liposomal doxorubicin: The Royal Marsden Hospital experience

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.10519-10519

2009

Volltextzugriff (PDF)

Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.10040-10040

2010

Volltextzugriff (PDF)

Systemic therapy in clear cell sarcoma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.10098-10098

2010

Volltextzugriff (PDF)

Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.10528-10528

2009

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Aktive Filter

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(199)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(123)
Life Sciences & Biomedicine
(95)
Humans
(92)
Female
(42)
Male
(34)
Adult
(29)
Middle Aged
(22)
Physical Sciences
(22)
Technology
(22)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Animals
(20)
Aged
(18)
Surgery
(18)
Chemistry
(17)
Materials Science
(17)
Radiology, Nuclear Medicine & Medical Imaging
(16)
Oncology
(14)
Genetics & Heredity
(12)
Magnetic Resonance Imaging
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Highly prevalent colorectal cancer-infiltrating LAP⁺ Foxp3⁻ T cells exhibit more potent immunosuppressive activity than Foxp3⁺ regulatory T cells

Elevated IL-33 expression is associated with pediatric eosinophilic esophagitis, and exogenous IL-33 promotes eosinophilic esophagitis development in mice

278. Immunological outcome in patients after resection of colorectal cancer

PMO-088A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression

How to Treat the Ewing's Family of Sarcomas in Adult Patients

PWE-151Cell-MediatedImmune Recognition of Cea Is Associated with Early Tumour Recurrence Following Resection of Colorectal Cancer

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

9421 The role of chemotherapy in aggressive fibromatosis

9404 A Phase II study of cediranib in patients with metastatic gastrointestinal stromal tumours (GIST) and metastatic soft tissue sarcoma (STS) (including alveolar soft part sarcoma [ASPS])

PWE-152SelectiveLoss of Oncofoetal Antigen 5T4-Specific T Cell Response Correlates with Progression of Colorectal Cancer

49 POSTER Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI)

126 INVITED New drug treatment for cancer in 2007 – real progress at last?

Neoadjuvant and Adjuvant Therapy for Extremity Soft Tissue Sarcomas

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma

7505 ORAL Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas

Chemotherapy in advanced pleomorphic sarcomas: The experience of the Royal Marsden Hospital (RMH)

Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma

Creatinine clearance and serum albumin as factors for encephalopathy with ambulatory 14-day infusional ifosfamide for advanced liposarcomas

The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group

Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined analysis from two European referral institutions

Treatment of aggressive fibromatosis with pegylated liposomal doxorubicin: The Royal Marsden Hospital experience

Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study

Systemic therapy in clear cell sarcoma

Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma

Aktive Filter

Suchergebnisse filtern